Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease

Meurice, Thibaud; Tricot, Olivier; Lemesle, Gilles; Deneve, Michel; Lejeune, Philippe; Biausque, Frédéric; Cordier, Christophe; Savoye, Christine; Hennebert, Olivier; Taghipour, K.; Sivery, B.; Pruvost, Philippe; Alaoui, Moulay; Carpentier, Laurent; Segrestin, Benoit; Lamblin, Nicolas; Bauters, Christophe

doi:10.1016/j.acvd.2015.01.007

Cited by 7 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, it has been demonstrated that the cardiovascular prognosis of diabetic patients with CAD undergoing percutaneous coronary intervention is worse when the level of glycosylated hemoglobin (HbA1c) is high . However, in a context of major improvement in secondary prevention, there is a lack of recent studies evaluating these issues in patients with stable CAD who are known to be at relatively low cardiovascular risk overall . In addition, although patients with CAD with diabetes mellitus (DM) have also been shown to be at higher risk of bleeding, an event with important prognostic consequences, whether this risk may vary according to DM control (HbA1c level) has not been established.…”

Section: Introductionmentioning

confidence: 99%

Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5‐Year CORONOR Registry

Lemesle

Meurice²,

Tricot

et al. 2018

JAHA

Self Cite

View full text Add to dashboard Cite

BackgroundThe relation between diabetes mellitus, glycemic control, and ischemic and bleeding events is poorly described in outpatients with stable coronary artery disease receiving modern secondary prevention.Methods and ResultsThe multicenter CORONOR (Suivi d'une cohorte de patients Coronariens stables en région Nord‐pas‐de‐Calais) registry enrolled 4184 outpatients with stable coronary artery disease, including 1297 patients (31%) with diabetes mellitus. A recent glycosylated hemoglobin (HbA1c) was available for 1146 diabetic patients, and 48% had HbA1c ≥7%. We analyzed 5‐year ischemic (cardiovascular death, myocardial infarction, and stroke) and bleeding (Bleeding Academic Research Consortium ≥3) outcomes, according to diabetic status and glycemic control. When compared with nondiabetic patients, the ischemic risk was higher in diabetic patients with HbA1c ≥7% (hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.25–1.93) but not in diabetic patients with HbA1c <7% (HR, 1.06; 95% CI, 0.83–1.36). Diabetic patients with HbA1c ≥7% were at higher risk than diabetic patients with HbA1c <7% (HR, 1.47; 95% CI, 1.09–1.98). When compared with nondiabetic patients, the bleeding risk was higher in diabetic patients, with HbA1c <7% (HR, 1.66; 95% CI, 1.04–2.67) and in those with HbA1c ≥7% (HR, 1.75; 95% CI, 1.07–2.86). No difference in bleeding risk was observed between diabetic patients with HbA1c ≥7% versus those with HbA1c <7%. Similar results were obtained when adjusted for baseline characteristics.ConclusionsThe 5‐year increased risk of ischemic events in patients with stable coronary artery disease with diabetes mellitus was restricted to those with HbA1c ≥7%. By contrast, the increase in bleeding risk associated with diabetes mellitus was observed in patients with HbA1c ≥7% and in patients with HbA1c <7%. The level of HbA1c should be taken into account for future research and may help physicians to manage prolonged antithrombotic therapies in this high‐risk subgroup.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5‐Year CORONOR Registry

Lemesle

Meurice²,

Tricot

et al. 2018

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

“…Отже, основні напрямки терапії ІХС, з точки зору доказової медицини, повинні бути спрямовані саме на ці фактори ризику. Недосконалість кардіологічної допомоги населенню і нераціональне використання заснованих на фактичних даних препаратів у пацієнтів з ІХС пов'язані з підвищеним ризиком несприятливого результату терапії [6] і високим рівнем серцево-судинної смертності [1,4,7,9,11,12].…”

unclassified

The results of frequency analysis of drug prescriptions for patients with ischemic heart disease as a quality criterion for pharmacotherapy

2016

View full text Add to dashboard Cite

Інститут підвищення кваліфікації спеціалістів фармації Національного фармацевтичного університету Національний фармацевтичний університет* Ключові слова: частотний аналіз; лікарські призначення; фармакотерапія; ішемічна хвороба серця

show abstract

Effect of left ventricular systolic dysfunction on secondary medical prevention and clinical outcome in stable coronary artery disease patients

Lamblin

Meurice²,

Tricot

et al. 2017

Archives of Cardiovascular Diseases

View full text Add to dashboard Cite

show abstract

Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease

Cited by 7 publications

References 17 publications

Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5‐Year CORONOR Registry

Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5‐Year CORONOR Registry

The results of frequency analysis of drug prescriptions for patients with ischemic heart disease as a quality criterion for pharmacotherapy

Effect of left ventricular systolic dysfunction on secondary medical prevention and clinical outcome in stable coronary artery disease patients

Contact Info

Product

Resources

About